Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMKA2PI)

Drug Name

Efpeglenatide Drug Info

Synonyms

Langlenatide; Efpeglenatide [INN]; Langlenatide [WHO-DD]; UNII-3M1V5Z2270; SCHEMBL19712179; 3M1V5Z2270; 1296200-77-5

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Phase 3	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucagon-like peptide 1 receptor (GLP1R)	TTVIMDE	GLP1R_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Glucagon-like peptide 1 receptor (GLP1R)	DTT	GLP1R	2	2.848	3.472	2.963

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Type-2 diabetes

ICD Disease Classification

5A11

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Glucagon-like peptide 1 receptor (GLP1R)	DTT	GLP1R	1.25E-01	0.17	1.26

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT03496298) Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)